One important metric to look for in a stock is an 80 or higher Relative Strength Rating. Corbus Pharmaceuticals now clears that threshold, with a jump from 61 to 87 Wednesday.
IBD's unique RS Rating identifies technical performance by using a 1 (worst) to 99 (best) score that shows how a stock's price performance over the trailing 52 weeks matches up against the rest of the market.
History reveals that the market's biggest winners typically have an RS Rating north of 80 in the early stages of their moves.
Looking For The Best Stocks To Buy And Watch? Start Here
Corbus Pharmaceuticals is not currently near a potential buy zone. See if the stock goes on to form a promising consolidation that could kick off a new price move.
Corbus Pharmaceuticals posted 0% EPS growth in its most recent report, while sales growth came in at -100%. Look for the next report on or around Nov. 6.
Corbus Pharmaceuticals earns the No. 205 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Exelixis and Halozyme Therapeutics are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
